To evaluate adherence to pre-exposure prophylaxis (PrEP) in a clinical trial of a population of men who have sex with men (MSM), to explore the influence of social psychology and objective factors (e.g., forgetting, too busy) on adherence, and to provide evidence for subsequent PrEP research.
The purpose of the study was to investigate the nursing students' levels of the knowledge, willingness, and attitudes toward first aid behavior as bystanders in road traffic accident and the related factors.
This paper proposes a hierarchical multi-label matcher for patch-based face recognition. In signature generation, a face image is iteratively divided into multi-level patches. Two different types of patch divisions and signatures are introduced for 2D facial image and texture-lifted image, respectively. The matcher training consists of three steps. First, local classifiers are built to learn the local matching of each patch. Second, the hierarchical relationships defined between local patches are used to learn the global matching of each patch. Three ways are introduced to learn the global matching: majority voting, l 1 -regularized weighting, and decision rule. Last, the global matchings of different levels are combined as the final matching. Experimental results on different face recognition tasks demonstrate the effectiveness of the proposed matcher at the cost of gallery generalization. Compared with the UR2D system, the proposed matcher improves the Rank-1 accuracy significantly by 3% and 0.18% on the UHDB31 dataset and IJB-A dataset, respectively.
The costimulatory receptor 4-1BB is expressed on activated immune cells, including activated T cells. Antibodies targeting 4-1BB enhance the proliferation and survival of antigen-stimulated T cells in vitro and promote CD8 T cell-dependent anti-tumor immunity in pre-clinical cancer models. We found that T regulatory (Treg) cells infiltrating human or murine tumors expressed high amounts of 4-1BB. Intra-tumoral Treg cells were preferentially depleted by anti-4-1BB mAbs in vivo. Anti-4-1BB mAbs also promoted effector T cell agonism to promote tumor rejection. These distinct mechanisms were competitive and dependent on antibody isotype and FcγR availability. Administration of anti-4-1BB IgG2a, which preferentially depletes Treg cells, followed by either agonistic anti-4-1BB IgG1 or anti-PD-1 mAb augmented anti-tumor responses in multiple solid tumor models. An antibody engineered to optimize both FcγR-dependent Treg cell depleting capacity and FcγR-independent agonism delivered enhanced anti-tumor therapy. These insights into the effector mechanisms of anti-4-1BB mAbs lay the groundwork for translation into the clinic.